Franziska Michor, Ph.D. - Publications

Affiliations: 
Harvard University, Cambridge, MA, United States 
Area:
Evolutionary Dynamics

120 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Yamamoto KN, Nakamura A, Liu LL, Stein S, Tramontano AC, Kartoun U, Shimizu T, Inoue Y, Asakuma M, Haeno H, Kong CY, Uchiyama K, Gonen M, Hur C, Michor F. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. Plos One. 14: e0215409. PMID 31026288 DOI: 10.1371/journal.pone.0215409  0.6
2019 Yamamoto KN, Liu LL, Nakamura A, Haeno H, Michor F. Stochastic Evolution of Pancreatic Cancer Metastases During Logistic Clonal Expansion. Jco Clinical Cancer Informatics. 1-11. PMID 30901235 DOI: 10.1200/CCI.18.00079  0.6
2018 Stein S, Zhao R, Haeno H, Vivanco I, Michor F. Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. Plos Computational Biology. 14: e1005924. PMID 29293494 DOI: 10.1371/journal.pcbi.1005924  0.6
2017 Maruvka YE, Mouw KW, Karlic R, Parasuraman P, Kamburov A, Polak P, Haradhvala NJ, Hess JM, Rheinbay E, Brody Y, Koren A, Braunstein LZ, D'Andrea A, Lawrence MS, Bass A, ... ... Michor F, et al. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nature Biotechnology. PMID 28892075 DOI: 10.1038/nbt.3966  0.48
2016 Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, Tsai PC, Casasent A, Waters J, Zhang H, Meric-Bernstam F, Michor F, Navin NE. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nature Genetics. PMID 27526321 DOI: 10.1038/ng.3641  1
2016 Wee B, Pietras A, Ozawa T, Bazzoli E, Podlaha O, Antczak C, Westermark B, Nelander S, Uhrbom L, Forsberg-Nilsson K, Djaballah H, Michor F, Holland EC. ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Scientific Reports. 6: 25956. PMID 27456282 DOI: 10.1038/srep25956  1
2016 Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades CS, Viselli S, Neuwirth R, Esseltine DL, Anderson KC, Ghobrial IM, San Miguel J, Richardson PG, Tomasson MH, Michor F. Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27006493 DOI: 10.1158/1078-0432.CCR-15-2793  1
2015 Altrock PM, Liu LL, Michor F. The mathematics of cancer: integrating quantitative models. Nature Reviews. Cancer. 15: 730-45. PMID 26597528 DOI: 10.1038/nrc4029  1
2015 Michor F, Beal K. Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. Cell. 163: 1059-1063. PMID 26590416 DOI: 10.1016/j.cell.2015.11.002  1
2015 Liu LL, Li F, Pao W, Michor F. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients. Plos One. 10: e0141665. PMID 26536620 DOI: 10.1371/journal.pone.0141665  1
2015 Foo J, Liu LL, Leder K, Riester M, Iwasa Y, Lengauer C, Michor F. An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. Plos Computational Biology. 11: e1004350. PMID 26379039 DOI: 10.1371/journal.pcbi.1004350  1
2015 Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Informatics. 14: 19-31. PMID 26244007 DOI: 10.4137/CIN.S19338  1
2015 Badri H, Pitter K, Holland EC, Michor F, Leder K. Optimization of radiation dosing schedules for proneural glioblastoma. Journal of Mathematical Biology. PMID 26094055 DOI: 10.1007/s00285-015-0908-x  1
2015 Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE. DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. Bmc Cancer. 15: 242. PMID 25886454 DOI: 10.1186/s12885-015-1192-2  1
2015 Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, ... ... Michor F, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nature Medicine. 21: 440-8. PMID 25849130 DOI: 10.1038/nm.3841  1
2015 Selmecki AM, Maruvka YE, Richmond PA, Guillet M, Shoresh N, Sorenson AL, De S, Kishony R, Michor F, Dowell R, Pellman D. Polyploidy can drive rapid adaptation in yeast. Nature. 519: 349-52. PMID 25731168 DOI: 10.1038/nature14187  1
2015 Ashcroft P, Michor F, Galla T. Stochastic tunneling and metastable states during the somatic evolution of cancer. Genetics. 199: 1213-28. PMID 25624316 DOI: 10.1534/genetics.114.171553  1
2015 Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, ... ... Michor F, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discovery. 5: 316-31. PMID 25572172 DOI: 10.1158/2159-8290.CD-14-0736  1
2015 Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer Nature Genetics. DOI: 10.1038/ng.3391  1
2015 Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y, Sahin I, Chiarini M, Manier S, Cea M, Aljawai Y, ... ... Michor F, et al. CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation Cell Reports. DOI: 10.1016/j.celrep.2015.06.059  1
2014 Shaknovich R, De S, Michor F. Epigenetic diversity in hematopoietic neoplasms. Biochimica Et Biophysica Acta. 1846: 477-84. PMID 25240947 DOI: 10.1016/j.bbcan.2014.09.003  1
2014 Olshen A, Tang M, Cortes J, Gonen M, Hughes T, Branford S, Quintás-Cardama A, Michor F. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica. 99: 1701-9. PMID 25216683 DOI: 10.3324/haematol.2013.085977  1
2014 Ozawa T, Riester M, Cheng YK, Huse JT, Squatrito M, Helmy K, Charles N, Michor F, Holland EC. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 26: 288-300. PMID 25117714 DOI: 10.1016/j.ccr.2014.06.005  1
2014 Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 514: 54-8. PMID 25079331 DOI: 10.1038/nature13556  1
2014 Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Zhao R, Michor F, Meric-Bernstam F, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 512: 155-60. PMID 25079324 DOI: 10.1038/nature13600  1
2014 Maruvka YE, Tang M, Michor F. On the validity of using increases in 5-year survival rates to measure success in the fight against cancer. Plos One. 9: e83100. PMID 25054541 DOI: 10.1371/journal.pone.0083100  1
2014 Podlaha O, De S, Gonen M, Michor F. Histone modifications are associated with transcript isoform diversity in normal and cancer cells. Plos Computational Biology. 10: e1003611. PMID 24901363 DOI: 10.1371/journal.pcbi.1003611  1
2014 Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, ... ... Michor F, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Medicine. 3: 835-44. PMID 24846059 DOI: 10.1002/cam4.262  1
2014 Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. Journal of the National Cancer Institute. 106. PMID 24700803 DOI: 10.1093/jnci/dju048  1
2014 Michor F, Weaver VM. Understanding tissue context influences on intratumour heterogeneity. Nature Cell Biology. 16: 301-2. PMID 24691256 DOI: 10.1038/ncb2942  1
2014 Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. Journal of Theoretical Biology. 355: 10-20. PMID 24681298 DOI: 10.1016/j.jtbi.2014.02.025  1
2014 Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, ... ... Michor F, et al. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1873-83. PMID 24486590 DOI: 10.1158/1078-0432.CCR-13-0759  1
2014 Leder K, Pitter K, Laplant Q, Hambardzumyan D, Ross BD, Chan TA, Holland EC, Michor F. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell. 156: 603-16. PMID 24485463 DOI: 10.1016/j.cell.2013.12.029  1
2014 Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, ... ... Michor F, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Reports. 6: 514-27. PMID 24462293 DOI: 10.1016/j.celrep.2013.12.041  1
2014 Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K. Genetic and phenotypic diversity in breast tumor metastases. Cancer Research. 74: 1338-48. PMID 24448237 DOI: 10.1158/0008-5472.CAN-13-2357-T  1
2014 Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA, Morin RD, Scott DW, Godley LA, Gascoyne RD, Melnick A, Campagne F, Shaknovich R. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 123: 1699-708. PMID 24385541 DOI: 10.1182/blood-2013-07-509885  1
2014 Randles A, Draeger E, Michor F. Analysis of pressure gradient across aortic stenosis with massively parallel computational simulations Computing in Cardiology. 41: 217-220.  1
2013 Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M, Holyoake TL. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology. 163: 674-6. PMID 24032404 DOI: 10.1111/bjh.12532  1
2013 Haeno H, Maruvka YE, Iwasa Y, Michor F. Stochastic Tunneling of Two Mutations in a Population of Cancer Cells. Plos One. 8: e65724. PMID 23840359 DOI: 10.1371/journal.pone.0065724  1
2013 Zhao R, Michor F. Patterns of proliferative activity in the colonic crypt determine crypt stability and rates of somatic evolution. Plos Computational Biology. 9: e1003082. PMID 23785264 DOI: 10.1371/journal.pcbi.1003082  1
2013 Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, ... ... Michor F, et al. Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell. 13: 117-30. PMID 23770079 DOI: 10.1016/j.stem.2013.05.004  1
2013 Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Research. 23: 1434-45. PMID 23733853 DOI: 10.1101/gr.152322.112  1
2013 Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, ... ... Michor F, et al. A physical sciences network characterization of non-tumorigenic and metastatic cells. Scientific Reports. 3: 1449. PMID 23618955 DOI: 10.1038/srep01449  1
2013 Liu L, De S, Michor F. DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. Nature Communications. 4: 1502. PMID 23422670 DOI: 10.1038/ncomms2502  1
2013 Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1070-80. PMID 23401451 DOI: 10.1200/JCO.2012.43.3912  1
2013 De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM, Cerchietti L, Gascoyne RD, Melnick A, Michor F. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. Plos Genetics. 9: e1003137. PMID 23326238 DOI: 10.1371/journal.pgen.1003137  1
2012 Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1583-93. PMID 22982659 DOI: 10.1097/JTO.0b013e31826146ee  1
2012 Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Garber JE, Fetten K, Michor F, Polyak K. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discovery. 2: 503-11. PMID 22628410 DOI: 10.1158/2159-8290.CD-11-0325  1
2012 Tang M, Foo J, Gönen M, Guilhot J, Mahon FX, Michor F. Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica. 97: 1553-61. PMID 22419579 DOI: 10.3324/haematol.2012.062844  1
2012 Iwami S, Haeno H, Michor F. A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. Plos Computational Biology. 8: e1002370. PMID 22359489 DOI: 10.1371/journal.pcbi.1002370  1
2012 Podlaha O, Riester M, De S, Michor F. Evolution of the cancer genome. Trends in Genetics : Tig. 28: 155-63. PMID 22342180 DOI: 10.1016/j.tig.2012.01.003  1
2012 Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 148: 362-75. PMID 22265421 DOI: 10.1016/j.cell.2011.11.060  1
2012 Cheng YK, Beroukhim R, Levine RL, Mellinghoff IK, Holland EC, Michor F. A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. Plos Computational Biology. 8: e1002337. PMID 22241976 DOI: 10.1371/journal.pcbi.1002337  1
2012 Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1323-33. PMID 22228636 DOI: 10.1158/1078-0432.CCR-11-2271  1
2012 Agus DB, Michor F. The sciences converge to fight cancer Nature Physics. 8: 773-774. DOI: 10.1038/nphys2464  1
2012 De S, Michor F. De and Michor respond Nature Biotechnology. 30: 1045-1046. DOI: 10.1038/nbt.2414  1
2011 Leder K, Foo J, Skaggs B, Gorre M, Sawyers CL, Michor F. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. Plos One. 6: e27682. PMID 22140458 DOI: 10.1371/journal.pone.0027682  1
2011 De S, Michor F. DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nature Biotechnology. 29: 1103-8. PMID 22101487 DOI: 10.1038/nbt.2030  1
2011 Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Molecular Pharmaceutics. 8: 2069-79. PMID 21995722 DOI: 10.1021/mp200270v  1
2011 Hambardzumyan D, Cheng YK, Haeno H, Holland EC, Michor F. The probable cell of origin of NF1- and PDGF-driven glioblastomas. Plos One. 6: e24454. PMID 21931722 DOI: 10.1371/journal.pone.0024454  1
2011 Michor F, Liphardt J, Ferrari M, Widom J. What does physics have to do with cancer? Nature Reviews. Cancer. 11: 657-70. PMID 21850037 DOI: 10.1038/nrc3092  1
2011 Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SN, Weinhold N, Reimers M, Clozel T, Luttrop K, Ekstrom TJ, Frank J, Vasanthakumar A, ... ... Michor F, et al. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 118: 3559-69. PMID 21828137 DOI: 10.1182/blood-2011-06-357996  1
2011 Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, ... ... Michor F, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine. 3: 90ra59. PMID 21734175 DOI: 10.1126/scitranslmed.3002356  1
2011 De S, Michor F. DNA secondary structures and epigenetic determinants of cancer genome evolution. Nature Structural & Molecular Biology. 18: 950-5. PMID 21725294 DOI: 10.1038/nsmb.2089  1
2011 Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 118: 1622-31. PMID 21653938 DOI: 10.1182/blood-2011-02-339267  1
2011 Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, ... ... Michor F, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 473: 230-3. PMID 21562564 DOI: 10.1038/nature09999  1
2011 Iwasa Y, Michor F. Evolutionary dynamics of intratumor heterogeneity. Plos One. 6: e17866. PMID 21479218 DOI: 10.1371/journal.pone.0017866  1
2011 Durrett R, Foo J, Leder K, Mayberry J, Michor F. Intratumor heterogeneity in evolutionary models of tumor progression. Genetics. 188: 461-77. PMID 21406679 DOI: 10.1534/genetics.110.125724  1
2011 Foo J, Leder K, Michor F. Stochastic dynamics of cancer initiation. Physical Biology. 8: 015002. PMID 21301064 DOI: 10.1088/1478-3975/8/1/015002  1
2011 De Vargas Roditi L, Michor F. Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis. Journal of Theoretical Biology. 273: 207-15. PMID 21194536 DOI: 10.1016/j.jtbi.2010.12.033  1
2011 Cheng YK, Beroukhim R, Levine RL, Mellinghoff IK, Michor F. Reply to Parsons: Many tumor types follow the monoclonal model of tumor initiation Proceedings of the National Academy of Sciences of the United States of America. 108: E16. DOI: 10.1073/pnas.1018584108  1
2010 Leder K, Holland EC, Michor F. The therapeutic implications of plasticity of the cancer stem cell phenotype. Plos One. 5: e14366. PMID 21179426 DOI: 10.1371/journal.pone.0014366  1
2010 Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prevention Research (Philadelphia, Pa.). 3: 1361-4. PMID 20959519 DOI: 10.1158/1940-6207.CAPR-10-0234  1
2010 Attolini CS, Cheng YK, Beroukhim R, Getz G, Abdel-Wahab O, Levine RL, Mellinghoff IK, Michor F. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proceedings of the National Academy of Sciences of the United States of America. 107: 17604-9. PMID 20864632 DOI: 10.1073/pnas.1009117107  1
2010 Danielson LS, Menendez S, Attolini CS, Guijarro MV, Bisogna M, Wei J, Socci ND, Levine DA, Michor F, Hernando E. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. The American Journal of Pathology. 177: 908-17. PMID 20558575 DOI: 10.2353/ajpath.2010.091150  1
2010 Durrett R, Foo J, Leder K, Mayberry J, Michor F. Evolutionary dynamics of tumor progression with random fitness values. Theoretical Population Biology. 78: 54-66. PMID 20488197 DOI: 10.1016/j.tpb.2010.05.001  1
2010 Riester M, Stephan-Otto Attolini C, Downey RJ, Singer S, Michor F. A differentiation-based phylogeny of cancer subtypes. Plos Computational Biology. 6: e1000777. PMID 20463876 DOI: 10.1371/journal.pcbi.1000777  1
2010 Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. The Journal of Clinical Investigation. 120: 636-44. PMID 20101094 DOI: 10.1172/JCI40724  1
2010 Foo J, Michor F. Evolution of resistance to anti-cancer therapy during general dosing schedules. Journal of Theoretical Biology. 263: 179-88. PMID 20004211 DOI: 10.1016/j.jtbi.2009.11.022  1
2010 Haeno H, Michor F. The evolution of tumor metastases during clonal expansion. Journal of Theoretical Biology. 263: 30-44. PMID 19917298 DOI: 10.1016/j.jtbi.2009.11.005  1
2009 Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. Plos Computational Biology. 5: e1000557. PMID 19893626 DOI: 10.1371/journal.pcbi.1000557  1
2009 Haeno H, Levine RL, Gilliland DG, Michor F. A progenitor cell origin of myeloid malignancies. Proceedings of the National Academy of Sciences of the United States of America. 106: 16616-21. PMID 19805346 DOI: 10.1073/pnas.0908107106  1
2009 Foo J, Drummond MW, Clarkson B, Holyoake T, Michor F. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. Plos Computational Biology. 5: e1000503. PMID 19749982 DOI: 10.1371/journal.pcbi.1000503  1
2009 Attolini CS, Michor F. Evolutionary theory of cancer. Annals of the New York Academy of Sciences. 1168: 23-51. PMID 19566702 DOI: 10.1111/j.1749-6632.2009.04880.x  1
2008 Liso A, Castiglione F, Cappuccio A, Stracci F, Schlenk RF, Amadori S, Thiede C, Schnittger S, Valk PJ, Döhner K, Martelli MF, Schaich M, Krauter J, Ganser A, Martelli MP, ... ... Michor F, et al. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica. 93: 1219-26. PMID 18603563 DOI: 10.3324/haematol.13209  1
2008 Michor F. Mathematical models of cancer stem cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2854-61. PMID 18539964 DOI: 10.1200/JCO.2007.15.2421  1
2007 Haeno H, Iwasa Y, Michor F. The evolution of two mutations during clonal expansion. Genetics. 177: 2209-21. PMID 18073428 DOI: 10.1534/genetics.107.078915  1
2007 Michor F. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia. Trends in Pharmacological Sciences. 28: 197-9. PMID 17412430 DOI: 10.1016/j.tips.2007.03.003  1
2007 Dingli D, Michor F, Antal T, Pacheco JM. The emergence of tumor metastases. Cancer Biology & Therapy. 6: 383-90. PMID 17312385  1
2007 Michor F. Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells (Dayton, Ohio). 25: 1114-8. PMID 17218393 DOI: 10.1634/stemcells.2006-0638  1
2007 Dingli D, Traulsen A, Michor F. Correction: (A)Symmetric Stem Cell Replication and Cancer Plos Computational Biology. 3: e83. DOI: 10.1371/JOURNAL.PCBI.0030083  0.44
2007 Michor F. Reply: The long-term response to imatinib treatment of CML [2] British Journal of Cancer. 96: 679-680. DOI: 10.1038/sj.bjc.6603604  1
2006 Michor F, Iwasa Y, Nowak MA. The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proceedings of the National Academy of Sciences of the United States of America. 103: 14931-4. PMID 17001000 DOI: 10.1073/pnas.0607006103  1
2006 Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells (Dayton, Ohio). 24: 2603-10. PMID 16931775 DOI: 10.1634/stemcells.2006-0136  1
2006 Iwasa Y, Nowak MA, Michor F. Evolution of resistance during clonal expansion. Genetics. 172: 2557-66. PMID 16636113 DOI: 10.1534/genetics.105.049791  1
2006 Michor F, Iwasa Y. Dynamics of metastasis suppressor gene inactivation. Journal of Theoretical Biology. 241: 676-89. PMID 16497335 DOI: 10.1016/j.jtbi.2006.01.006  1
2006 Michor F, Nowak MA, Iwasa Y. Evolution of resistance to cancer therapy. Current Pharmaceutical Design. 12: 261-71. PMID 16454743 DOI: 10.2174/138161206775201956  1
2006 Nowak MA, Michor F, Iwasa Y. Genetic instability and clonal expansion. Journal of Theoretical Biology. 241: 26-32. PMID 16405914 DOI: 10.1016/j.jtbi.2005.11.012  1
2006 Brumer Y, Michor F, Shakhnovich EI. Genetic instability and the quasispecies model. Journal of Theoretical Biology. 241: 216-22. PMID 16386760 DOI: 10.1016/j.jtbi.2005.11.018  1
2006 Michor F, Nowak MA, Iwasa Y. Stochastic dynamics of metastasis formation. Journal of Theoretical Biology. 240: 521-30. PMID 16343545 DOI: 10.1016/j.jtbi.2005.10.021  1
2006 Hauert C, Michor F, Nowak MA, Doebeli M. Synergy and discounting of cooperation in social dilemmas. Journal of Theoretical Biology. 239: 195-202. PMID 16242728 DOI: 10.1016/j.jtbi.2005.08.040  1
2005 Michor F, Iwasa Y, Lengauer C, Nowak MA. Dynamics of colorectal cancer. Seminars in Cancer Biology. 15: 484-93. PMID 16055342 DOI: 10.1016/j.semcancer.2005.06.005  1
2005 Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 435: 1267-70. PMID 15988530 DOI: 10.1038/nature03669  1
2005 Michor F. Chromosomal instability and human cancer. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 360: 631-5. PMID 15897185 DOI: 10.1098/rstb.2004.1617  1
2005 Iwasa Y, Michor F, Komarova NL, Nowak MA. Population genetics of tumor suppressor genes. Journal of Theoretical Biology. 233: 15-23. PMID 15615616 DOI: 10.1016/j.jtbi.2004.09.001  1
2005 Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis? Seminars in Cancer Biology. 15: 43-9. PMID 15613287 DOI: 10.1016/j.semcancer.2004.09.007  1
2005 Iwasa Y, Michor F, Nowak MA. Virus evolution within patients increases pathogenicity. Journal of Theoretical Biology. 232: 17-26. PMID 15498589 DOI: 10.1016/j.jtbi.2004.07.016  1
2004 Jones NA, Wei X, Flower DR, Wong M, Michor F, Saag MS, Hahn BH, Nowak MA, Shaw GM, Borrow P. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. The Journal of Experimental Medicine. 200: 1243-56. PMID 15545352 DOI: 10.1084/jem.20040511  1
2004 Nowak MA, Michor F, Komarova NL, Iwasa Y. Evolutionary dynamics of tumor suppressor gene inactivation. Proceedings of the National Academy of Sciences of the United States of America. 101: 10635-8. PMID 15252197 DOI: 10.1073/pnas.0400747101  1
2004 Iwasa Y, Michor F, Nowak M. Some basic properties of immune selection. Journal of Theoretical Biology. 229: 179-88. PMID 15207473 DOI: 10.1016/j.jtbi.2004.03.013  1
2004 Iwasa Y, Michor F, Nowak MA. Stochastic tunnels in evolutionary dynamics. Genetics. 166: 1571-9. PMID 15082570 DOI: 10.1534/genetics.166.3.1571  1
2004 Michor F, Iwasa Y, Nowak MA. Dynamics of cancer progression. Nature Reviews. Cancer. 4: 197-205. PMID 14993901 DOI: 10.1038/nrc1295  1
2004 Michor F, Iwasa Y, Rajagopalan H, Lengauer C, Nowak MA. Linear model of colon cancer initiation. Cell Cycle (Georgetown, Tex.). 3: 358-62. PMID 14726709  1
2004 Iwasa Y, Michor F, Nowak MA. Evolutionary dynamics of invasion and escape. Journal of Theoretical Biology. 226: 205-14. PMID 14643190 DOI: 10.1016/j.jtbi.2003.08.014  1
2003 Iwasa Y, Michor F, Nowak MA. Evolutionary dynamics of escape from biomedical intervention. Proceedings. Biological Sciences / the Royal Society. 270: 2573-8. PMID 14728779 DOI: 10.1098/rspb.2003.2539  1
2003 Nowak MA, Michor F, Iwasa Y. The linear process of somatic evolution. Proceedings of the National Academy of Sciences of the United States of America. 100: 14966-9. PMID 14657359 DOI: 10.1073/pnas.2535419100  1
2003 Michor F, Frank SA, May RM, Iwasa Y, Nowak MA. Somatic selection for and against cancer. Journal of Theoretical Biology. 225: 377-82. PMID 14604590 DOI: 10.1016/S0022-5193(03)00267-4  1
2003 Michor F, Nowak MA, Frank SA, Iwasa Y. Stochastic elimination of cancer cells. Proceedings. Biological Sciences / the Royal Society. 270: 2017-24. PMID 14561289 DOI: 10.1098/rspb.2003.2483  1
2003 Michor F, Iwasa Y, Komarova NL, Nowak MA. Local regulation of homeostasis favors chromosomal instability. Current Biology : Cb. 13: 581-4. PMID 12676089 DOI: 10.1016/S0960-9822(03)00172-6  1
2002 Michor F, Nowak MA. Evolution: the good, the bad and the lonely. Nature. 419: 677, 679. PMID 12384681 DOI: 10.1038/419677a  1
Show low-probability matches.